GENEVA, Switzerland November 22, 2021 – Obseva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health,today announced that the New Drug Application…Original Article
You may also like
Merus Receives FDA Extension of PDUFA for Zenocutuzumab
Ionis Announces FDA Acceptance of New Drug Application...
Dizal Submits New Drug Application to the U.S. FDA for...
Neurotech Provides Update on BLA for NT-501 as a...
Unicycive Therapeutics Announces U.S. FDA Acceptance...
Aldeyra Therapeutics Announces FDA Acceptance for...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.